Lee N H, Fryer A D, Forray C, el-Fakahany E E
Department of Pharmacology and Toxicology, University of Maryland School of Pharmacy, Baltimore.
J Pharmacol Exp Ther. 1989 Dec;251(3):992-9.
The allosteric effects and subtype selectivity of methoctramine on neuronal muscarinic receptors in N1E-115 cells and two different rat brain regions (cerebral cortex and striatum) were assessed. Saturation isotherms of [3H]N-methylscopolamine binding, performed in N1E-115 cells and dissociated cerebral cortex, showed that methoctramine reduced the Bmax in a concentration-dependent manner. Furthermore, this compound slowed the rate of dissociation of bound [3H]N-methylscopolamine in the same tissue preparations. Low concentrations of methoctramine (less than or equal to 1 microM) antagonized the M1-linked phosphoinositide response in N1E-115 cells and dissociated cerebral cortex in an apparent competitive mechanism. However, methoctramine exhibited noncompetitive effects at higher concentrations in N1E-115 cells. Observation of a similar effect in cerebrocortical cells was precluded since methoctramine by itself, at concentrations higher than 1 microM, stimulated inositol phosphate formation. The stimulatory effect of methoctramine on phosphoinositide hydrolysis was not blocked by atropine. A solely competitive mode of antagonism by methoctramine was observed for the inhibition of cAMP formation (a noncardiac-M2 coupled response) in N1E-115 cells and dissociated striatum. This antagonism was evident even at concentrations of methoctramine that noncompetitively antagonized the M1 response. Anomalously, methoctramine alone inhibited cAMP formation in dissociated striatum at concentrations of greater than or equal to 30 microM. Atropine was ineffective at blocking this effect. Methoctramine failed to demonstrate muscarinic receptor subtype selectively in blocking these two second messenger responses. This nonselectivity was supported by indirect binding experiments involving methoctramine and [3H]N-methylscopolamine. The data presented here demonstrate that methoctramine binds to a secondary site(s) associated with neuronal muscarinic receptors. Furthermore, methoctramine exhibits different mechanisms of antagonism and displays poor selectivity for the M1-linked phosphoinositide and noncardiac-M2 linked cAMP responses.
评估了美索曲明对N1E-115细胞以及两种不同大鼠脑区(大脑皮层和纹状体)中神经元毒蕈碱受体的变构效应和亚型选择性。在N1E-115细胞和分离的大脑皮层中进行的[3H]N-甲基东莨菪碱结合饱和等温线实验表明,美索曲明以浓度依赖性方式降低了Bmax。此外,该化合物在相同的组织制剂中减缓了结合的[3H]N-甲基东莨菪碱的解离速率。低浓度的美索曲明(小于或等于1 microM)以明显的竞争性机制拮抗N1E-115细胞和分离的大脑皮层中与M1相关的磷酸肌醇反应。然而,美索曲明在N1E-115细胞中较高浓度时表现出非竞争性效应。由于美索曲明本身在高于1 microM的浓度下会刺激肌醇磷酸的形成,因此无法在大脑皮层细胞中观察到类似的效应。美索曲明对磷酸肌醇水解的刺激作用不受阿托品的阻断。在N1E-115细胞和分离的纹状体中,观察到美索曲明对cAMP形成(一种非心脏M2偶联反应)的抑制作用仅表现为竞争性拮抗模式。即使在美索曲明非竞争性拮抗M1反应的浓度下,这种拮抗作用也很明显。异常的是,美索曲明单独在大于或等于30 microM的浓度下会抑制分离的纹状体中的cAMP形成。阿托品无法阻断这种效应。美索曲明在阻断这两种第二信使反应时未能表现出毒蕈碱受体亚型选择性。涉及美索曲明和[3H]N-甲基东莨菪碱的间接结合实验支持了这种非选择性。此处呈现的数据表明,美索曲明与神经元毒蕈碱受体相关的二级位点结合。此外,美索曲明表现出不同的拮抗机制,并且对与M1相关的磷酸肌醇和非心脏M2相关的cAMP反应的选择性较差。